Basit öğe kaydını göster

dc.contributor.authorOzyurek, Hamit
dc.contributor.authorTurker, Hande
dc.contributor.authorAkbalik, Mehtap
dc.contributor.authorBayrak, Ayse Oytun
dc.contributor.authorInce, Hulya
dc.contributor.authorDuru, Feride
dc.date.accessioned2020-06-21T15:24:33Z
dc.date.available2020-06-21T15:24:33Z
dc.date.issued2007
dc.identifier.issn0888-0018
dc.identifier.urihttps://doi.org/10.1080/08880010701451327
dc.identifier.urihttps://hdl.handle.net/20.500.12712/20265
dc.descriptionWOS: 000251931700016en_US
dc.descriptionPubMed: 17710662en_US
dc.description.abstractVincristine is a commonly used antineoplastic drug and frequently causes neurotoxicity. Here the authors report a 4-year-old boy with acute lymphoblastic leukemia in whom vincristine-induced peripheral and cranial neuropathy developed during remission induction therapy. The patient seemed to benefit from pyridoxine and pyridostigmine therapy greatly and this therapy is recommended in patients with severe vincristine-induced neuropathy.en_US
dc.language.isoengen_US
dc.publisherTaylor & Francis Incen_US
dc.relation.isversionof10.1080/08880010701451327en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectneurotoxicityen_US
dc.subjectpyridostigmineen_US
dc.subjectpyridoxineen_US
dc.subjectvincristineen_US
dc.titlePyridoxine and pyridostigmine treatment in vincristine-induced neuropathyen_US
dc.typearticleen_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume24en_US
dc.identifier.issue05.Augen_US
dc.identifier.startpage447en_US
dc.identifier.endpage452en_US
dc.relation.journalPediatric Hematology and Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster